AC Immune Ltd (ACIU)

AC Immune Ltd (ACIU) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $256M; returns 1 day -3.2%, 1 week +1.3%, 1 year -13.9%.

AC Immune SA is a clinical-stage Swiss biopharmaceutical company specializing in precision medicine for neurodegenerative diseases. Its business model is built on two proprietary technology platforms: SupraAntigen (biologics) and Morphomer (small molecules). Revenue is primarily derived from strategic partnership milestones and upfront payments rather than commercial product sales.

Groups ACIU belongs to

• Alzheimer's Disease
• Biotechnology
• Neuroscience
• Clinical Stage Biotech
• Precision Medicine
• Neurological Disorders
• Drug Discovery
• Biopharmaceutical
• Life Sciences
• Strategic Partnerships

ACIU financial model: income statement, cash flow and balance sheet